Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9951442 | 0.85 | ATR (0.48) | CYP17A1NAMPTPSMB8MAPKAPK2MAP4K4 | |
| SCHEMBL22110342 | 0.81 | MAPKAPK2 (0.47) | CYP17A1NAMPTPSMB8MAPKAPK2MAP4K4 | |
| SCHEMBL12517613 | 0.81 | NAMPT (0.45) | CYP17A1NAMPTPSMB8MAPKAPK2MAP4K4 | |
| SCHEMBL1548181 | 0.81 | MAPKAPK2 (0.47) | CYP17A1NAMPTPSMB8MAPKAPK2MAP4K4 | |
| SCHEMBL2012546 | 0.80 | NAMPT (0.50) | CYP17A1NAMPTPSMB8MAPKAPK2MAP4K4 | |
| SCHEMBL21885914 | 0.79 | CYP17A1 (0.45) | CYP17A1NAMPTPSMB8MAPKAPK2MAP4K4 | |
| SCHEMBL25547875 | 0.79 | CYP17A1 (0.45) | CYP17A1NAMPTPSMB8MAPKAPK2MAP4K4 | |
| SCHEMBL31363779 | 0.78 | NAMPT (0.51) | CYP17A1NAMPTPSMB8MAPKAPK2MAP4K4 | |
| SCHEMBL19180758 | 0.77 | NAMPT (0.54) | CYP17A1NAMPTPSMB8MAPKAPK2MAP4K4 | |
| SCHEMBL22498630 | 0.77 | CYP17A1 (0.43) | CYP17A1NAMPTPSMB8MAPKAPK2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | SHOUTI INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | APLNR, AGTR1, AGTR2 | CYP17A1 2554/4885NAMPT 3269/4885PSMB8 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.